NurExone Biologic Inc. is a pharmaceutical company which involved in developing a platform for biologically guided exosome-based therapies to be delivered, non-invasively, to patients who have suffered Central Nervous System injuries. The Company's principal product includes ExoPTEN. NurExone Biologic Inc. is based in HAIFA, Israel.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-5.04M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 26.66 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -430.93% |
| Return on Assets (Trailing 12 Months) | -259.04% |
| Current Ratio (Most Recent Fiscal Quarter) | 1.33 |
| Quick Ratio (Most Recent Fiscal Quarter) | 1.33 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.02 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.02 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.08 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.08 |
| Exchange | -- |
| Sector | -- |
| Industry | -- |
| Common Shares Outstanding | 90.68M |
| Free Float | -- |
| Market Capitalization | $42.56M |
| Average Volume (Last 20 Days) | 1492.15 |
| Beta (Past 60 Months) | -0.46 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | -- |
| Percentage Held By Institutions (Latest 13F Reports) | -- |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |